{"document": {"publication": "Tag My News", "full_text": "britain's healthcare cost watchdog nice has recommended against using bristol-myers squibb's rheumatoid arthritis drug orencia on the state health service as a second-line treatment.", "title": "uk's cost agency rebuffs bristol arthritis drug", "line_count": 1, "filename": "20019", "publication_date": "30-03-2011 20:22:23", "lines_and_colors": [["britain's healthcare cost watchdog nice has recommended against using bristol-myers squibb's rheumatoid arthritis drug orencia on the state health service as a second-line treatment.", {}]]}}